Ac-DEVD-CMK
(Synonyms: Ac-Asp-Glu-Val-Asp-CMK,Caspase-3 Inhibitor III) 目录号 : GC10951An inhibitor of caspase-3
Cas No.:285570-60-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ac-DEVD-CMK is a cell-permeable and irreversible caspase-3 inhibitor [1][2][3].
Apoptosis is a process of programmed cell death that occurs in multicellular organisms. Caspase are a family of protease enzymes playing essential roles in programmed cell death (including apoptosis, pyroptosis and necroptosis) and inflammation. Caspase activation is a major event in apoptosis. Caspase-3 cleaves and activates caspases 6 and 7, and is processed and activated by caspases 8, 9, and 10 [1][2][3].
Ac-DEVD-CMK (Ac-Asp-Glu-Val-Asp-CH2Cl) is a cell-permeable, irreversible and specific caspase-3 inhibitor. In coronary occlusion/reperfusion rat isolated hearts, Ac-DEVD-CMK reduced infarct size (the percentage of infarction 27.8+3.3% vs control 38.5+2.6%), suggesting that caspase inhibition during early reperfusion protected myocardium against lethal reperfusion injury [1]. In BL41 cells, Ac-DEVD-CMK partially inhibited Mn2+-induced apoptosis and PARP cleavage, and partially blocked B cell death by 37% even at 100 μM [2]. Ac-DEVD-CMK significantly blocked neurotoxicity at 24 hr after 1 hr of SIN-1 exposure and also protected against neurotoxicity at 24 hr after 90 min of zinc (75 μM) exposure. Ac-DEVD-CMK completely blocked SIN-1-induced activation of caspase-3 [3].
References:
[1]. Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000 May;130(2):197-200.
[2]. Schrantz N, Blanchard DA, Mitenne F, et al. Manganese induces apoptosis of human B cells: caspase-dependent cell death blocked by bcl-2. Cell Death Differ. 1999 May;6(5):445-53.
[3]. Zhang Y, Wang H, Li J, et al. Peroxynitrite-induced neuronal apoptosis is mediated by intracellular zinc release and 12-lipoxygenase activation. J Neurosci. 2004 Nov 24;24(47):10616-27.
Cas No. | 285570-60-7 | SDF | |
别名 | Ac-Asp-Glu-Val-Asp-CMK,Caspase-3 Inhibitor III | ||
化学名 | N-acetyl-L-α-aspartyl-L-α-glutamyl-N-[(1S)-1-(carboxymethyl)-3-chloro-2-oxopropyl]-L-valinamide | ||
Canonical SMILES | CC(N[C@@H](CC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC(O)=O)C(CCl)=O)=O)=O)=O)=O | ||
分子式 | C21H31ClN4O11 | 分子量 | 551.0 |
溶解度 | ≤50mg/ml in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.8149 mL | 9.0744 mL | 18.1488 mL |
5 mM | 0.363 mL | 1.8149 mL | 3.6298 mL |
10 mM | 0.1815 mL | 0.9074 mL | 1.8149 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。